Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

360 ARTÍCULOS , VIENDO DEL 76 AL 90

A clinical perspective: anti tau's treatment in Alzheimer's disease

Fuentes P, Catalan J.

Curr Alzheimer Res. 2011 Sep;8(6):686-8. doi: 10.2174/156720511796717221.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. doi: 10.2174/156720511796717122.

Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies

Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R.

Curr Alzheimer Res. 2011 Sep;8(6):659-65. doi: 10.2174/156720511796717177.

Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers

Calon F.

Curr Alzheimer Res. 2011 Aug;8(5):470-8. doi: 10.2174/156720511796391881.

Nutritional approaches to modulate oxidative stress in Alzheimer's disease

Pocernich CB, Lange ML, Sultana R, Butterfield DA.

Curr Alzheimer Res. 2011 Aug;8(5):452-69. doi: 10.2174/156720511796391908.

The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms

Subaiea GM, Alansi BH, Serra DA, Alwan M, Zawia NH.

Curr Alzheimer Res. 2011 Dec;8(8):860-7. doi: 10.2174/156720511798192691.

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial

Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B.

J Alzheimers Dis. 2011;26(2):211-20. doi: 10.3233/JAD-2011-110134.

Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease

Sodhi RK, Singh N, Jaggi AS.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):115-24. doi: 10.1007/s00210-011-0654-6. Epub 2011 May 24.

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A.

BMC Neurol. 2011 May 25;11:57. doi: 10.1186/1471-2377-11-57.

Transdermal rivastigmine: management of cutaneous adverse events and review of the literature

Greenspoon J, Herrmann N, Adam DN.

CNS Drugs. 2011 Jul;25(7):575-83. doi: 10.2165/11592230-000000000-00000.

Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease

Voronkov M, Braithwaite SP, Stock JB.

Future Med Chem. 2011 May;3(7):821-33. doi: 10.4155/fmc.11.47.

A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease

Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A.

Int J Clin Pract. 2011 Jul;65(7):790-6. doi: 10.1111/j.1742-1241.2011.02713.x. Epub 2011 Jun 6.

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease

Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, Li S, Hsu HA, Suhy J, Fridman M, Perhach JL.

Alzheimers Dement. 2011 Jul;7(4):425-35. doi: 10.1016/j.jalz.2010.09.003. Epub 2011 Jun 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias